Analysts Set Celgene Corporation (CELG) PT at $151.29

Celgene Corporation (NASDAQ:CELG) has earned a consensus recommendation of “Buy” from the twenty-nine research firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and twenty-two have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $151.36.

Several equities analysts recently commented on the company. Vetr upgraded Celgene Corporation from a “hold” rating to a “buy” rating and set a $146.58 target price for the company in a research report on Friday. Royal Bank Of Canada restated a “buy” rating and set a $173.00 target price on shares of Celgene Corporation in a research report on Thursday. Morgan Stanley cut Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research report on Thursday. Cantor Fitzgerald reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene Corporation in a report on Tuesday, September 26th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene Corporation in a report on Thursday, September 21st.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/09/analysts-set-celgene-corporation-celg-pt-at-151-29.html.

In other news, Director Ernest Mario sold 18,506 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilla Kaplan sold 7,500 shares of the stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares in the company, valued at $10,264,010.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,233 shares of company stock worth $6,268,259. Company insiders own 0.95% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Beacon Financial Group bought a new position in shares of Celgene Corporation during the 3rd quarter valued at $351,000. Centre Asset Management LLC bought a new position in shares of Celgene Corporation during the 3rd quarter valued at $5,878,000. Neville Rodie & Shaw Inc. lifted its holdings in shares of Celgene Corporation by 4.7% during the 3rd quarter. Neville Rodie & Shaw Inc. now owns 70,468 shares of the biopharmaceutical company’s stock valued at $10,276,000 after buying an additional 3,150 shares during the period. Eqis Capital Management Inc. lifted its holdings in shares of Celgene Corporation by 16.5% during the 3rd quarter. Eqis Capital Management Inc. now owns 40,165 shares of the biopharmaceutical company’s stock valued at $5,857,000 after buying an additional 5,685 shares during the period. Finally, Park National Corp OH lifted its holdings in shares of Celgene Corporation by 11.5% during the 3rd quarter. Park National Corp OH now owns 4,125 shares of the biopharmaceutical company’s stock valued at $601,000 after buying an additional 426 shares during the period. 79.36% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (CELG) traded up 0.04% during mid-day trading on Wednesday, hitting $139.27. The company had a trading volume of 3,445,662 shares. The company’s 50-day moving average is $139.31 and its 200 day moving average is $129.53. The company has a market capitalization of $108.96 billion, a PE ratio of 43.13 and a beta of 1.89. Celgene Corporation has a one year low of $96.93 and a one year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the business earned $1.44 earnings per share. The firm’s revenue was up 18.7% on a year-over-year basis. On average, equities

Several equities analysts recently commented on the company. Vetr upgraded Celgene Corporation from a “hold” rating to a “buy” rating and set a $146.58 target price for the company in a research report on Friday. Royal Bank Of Canada restated a “buy” rating and set a $173.00 target price on shares of Celgene Corporation in a research report on Thursday. Morgan Stanley cut Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research report on Thursday. Cantor Fitzgerald reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene Corporation in a report on Tuesday, September 26th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $162.00 price objective on shares of Celgene Corporation in a report on Thursday, September 21st.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2017/10/09/analysts-set-celgene-corporation-celg-pt-at-151-29.html.

In other news, Director Ernest Mario sold 18,506 shares of the stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilla Kaplan sold 7,500 shares of the stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now directly owns 76,301 shares in the company, valued at $10,264,010.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,233 shares of company stock worth $6,268,259. Company insiders own 0.95% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Beacon Financial Group bought a new position in shares of Celgene Corporation during the 3rd quarter valued at $351,000. Centre Asset Management LLC bought a new position in shares of Celgene Corporation during the 3rd quarter valued at $5,878,000. Neville Rodie & Shaw Inc. lifted its holdings in shares of Celgene Corporation by 4.7% during the 3rd quarter. Neville Rodie & Shaw Inc. now owns 70,468 shares of the biopharmaceutical company’s stock valued at $10,276,000 after buying an additional 3,150 shares during the period. Eqis Capital Management Inc. lifted its holdings in shares of Celgene Corporation by 16.5% during the 3rd quarter. Eqis Capital Management Inc. now owns 40,165 shares of the biopharmaceutical company’s stock valued at $5,857,000 after buying an additional 5,685 shares during the period. Finally, Park National Corp OH lifted its holdings in shares of Celgene Corporation by 11.5% during the 3rd quarter. Park National Corp OH now owns 4,125 shares of the biopharmaceutical company’s stock valued at $601,000 after buying an additional 426 shares during the period. 79.36% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (CELG) traded up 0.04% during mid-day trading on Wednesday, hitting $139.27. The company had a trading volume of 3,445,662 shares. The company’s 50-day moving average is $139.31 and its 200 day moving average is $129.53. The company has a market capitalization of $108.96 billion, a PE ratio of 43.13 and a beta of 1.89. Celgene Corporation has a one year low of $96.93 and a one year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the previous year, the business earned $1.44 earnings per share. The firm’s revenue was up 18.7% on a year-over-year basis. On average, equities research analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply